{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T00:14:56Z","timestamp":1794356096244,"version":"4.9.0"},"reference-count":12,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2004,8,24]],"date-time":"2004-08-24T00:00:00Z","timestamp":1093305600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Dermatology"],"published-print":{"date-parts":[[2006,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Objectives\u2002<\/jats:bold> An open\u2010label study was performed to assess the efficacy and safety of terbinafine in the treatment of eumycetoma.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> Single\u2010center, open\u2010label study, including 27 patients with signs and symptoms of eumycetoma which had developed within 5\u00a0years and was confirmed by mycological examination. The intention\u2010to\u2010treat population (<jats:italic>n<\/jats:italic>\u00a0=\u00a023) received 500\u00a0mg of terbinafine bid for 24\u201348\u00a0weeks.<\/jats:p><jats:p>Efficacy evaluations included clinical signs and symptoms (e.g. sinuses open or closed, degree of tumefaction, and emission of grains either present or absent); mycological examinations from Week 24 onwards; and investigators\u2019 overall assessment of efficacy (cure, improved since baseline, unchanged since baseline, or deterioration since baseline). Safety evaluations included monitoring of adverse events, laboratory assessments, vital signs and physical examinations.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Good clinical improvement was seen in patients who completed the study (<jats:italic>n<\/jats:italic>\u00a0=\u00a020). Tumefaction was absent or improved in 80% of patients; sinuses were closed in 50% of patients, and grain emissions were absent in 65% of patients. Of the 16 patients who had repeat mycological assessment, four (25%) were mycologically cured. In the investigators\u2019 overall opinion at the end of the study, five (25%) were cured and 11 (55%) were clinically improved. The majority of adverse events reported were mild to moderate, and consistent with the known tolerability profile of terbinafine.<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold> High\u2010dose terbinafine (1000\u00a0mg\/day) is well tolerated and clinically effective in patients with eumycetoma, a difficult\u2010to\u2010treat subcutaneous mycoses.<\/jats:p>","DOI":"10.1111\/j.1365-4632.2004.02392.x","type":"journal-article","created":{"date-parts":[[2006,1,20]],"date-time":"2006-01-20T17:31:58Z","timestamp":1137778318000},"page":"154-157","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Clinical efficacy and safety of oral terbinafine in fungal mycetoma"],"prefix":"10.1111","volume":"45","author":[{"given":"Bassirou","family":"N'Diaye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mame T.","family":"Dieng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlies","family":"Stockmeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Bakshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,8,24]]},"reference":[{"key":"e_1_2_7_2_2","unstructured":"WelshO Vera\u2010CabreraL Salinas\u2010CarmonaM.Mycetoma.http:\/\/www.emedicine.com."},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199243020-00010"},{"key":"e_1_2_7_4_2","first-page":"275","article-title":"Antifungal activity and mechanism of action of terbinafine","volume":"8","author":"Ryder NS","year":"1997","journal-title":"Rev Contemp Pharmacother"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1992.tb00001.x"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-280X.1998.00154.x"},{"key":"e_1_2_7_7_2","unstructured":"KLakhdar et al.Personal communication."},{"key":"e_1_2_7_8_2","first-page":"722","article-title":"Mycetoma","volume":"131","author":"Engelkens HJ","year":"1994","journal-title":"Br J Dermatol"},{"key":"e_1_2_7_9_2","first-page":"261","article-title":"Histopathologie des myc\u00e9tomes","volume":"52","author":"Destombe P.","year":"1972","journal-title":"Ann Soc Belg Med"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.1800791107"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(08)81277-7"},{"key":"e_1_2_7_12_2","doi-asserted-by":"crossref","unstructured":"ChapmanP PappasP KauffmanC et al.Comparative evaluation of the efficacy and safety of two doses of terbinafine (500 and 1000 mg\/day) in the treatment of cutaneous or lymphocutaneous sporotrichosis.Mycoses2004;47:62\u201368.","DOI":"10.1046\/j.1439-0507.2003.00953.x"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.3109\/09546639809160714"}],"container-title":["International Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-4632.2004.02392.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-4632.2004.02392.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T20:29:45Z","timestamp":1697315385000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-4632.2004.02392.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,8,24]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,2]]}},"alternative-id":["10.1111\/j.1365-4632.2004.02392.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-4632.2004.02392.x","archive":["Portico"],"relation":{},"ISSN":["0011-9059","1365-4632"],"issn-type":[{"value":"0011-9059","type":"print"},{"value":"1365-4632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,8,24]]},"assertion":[{"value":"2004-08-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}